Dario Mirabelli Selected Research

Asbestos

1/2022	Pleural mesothelioma risk by industry and occupation: results from the Multicentre Italian Study on the Etiology of Mesothelioma (MISEM).
1/2022	Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment.
6/2021	Diagnosis of lung cancer: a necropsy-based study of 128 cases (1997-2016).
5/2021	New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment.
1/2021	Is Mesothelioma Unrelated to the Lung Asbestos Burden? Comment on Visonà et al. Inorganic Fiber Lung Burden in Subjects with Occupational and/or Anthropogenic Environmental Asbestos Exposure in Broni (Pavia, Northern Italy): An SEM-EDS Study on Autoptic Samples. Int. J. Environ. Res. Public Health 2021, 18, 2053.
1/2021	Authors' response: Mezei et al's "Comments on a recent case-control study of malignant mesothelioma of the pericardium and the tunica vaginalis testis".
11/2020	DNA Methylation of FKBP5 as Predictor of Overall Survival in Malignant Pleural Mesothelioma.
11/2020	Association between asbestos exposure and pericardial and tunica vaginalis testis malignant mesothelioma: a case-control study and epidemiological remarks.
1/2020	[Asbestos exposure and related diseases among friction products workers (1971-2016)].
1/2020	Factors Affecting Asbestosis Mortality Among Asbestos-Cement Workers in Italy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dario Mirabelli Research Topics

Disease

38	Mesothelioma 01/2022 - 07/2007
31	Malignant Mesothelioma 01/2022 - 07/2007
21	Neoplasms (Cancer) 05/2021 - 04/2006
15	Lung Neoplasms (Lung Cancer) 01/2022 - 09/2004
6	Asbestosis 06/2021 - 01/2019
2	Carcinogenesis 10/2017 - 08/2008
2	Leukemia 12/2012 - 11/2008
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2022
1	Rare Diseases (Rare Disease) 11/2020
1	Biliary Tract Diseases 07/2015
1	Mucoepidermoid Carcinoma 01/2015
1	Renal Cell Carcinoma (Grawitz Tumor) 06/2013
1	Urinary Bladder Neoplasms (Bladder Cancer) 12/2012
1	Lymphoid Leukemia 11/2008
1	Multiple Myeloma 11/2008
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2008
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2008
1	Lymphoma (Lymphomas) 09/2006
1	Hodgkin Disease (Hodgkin's Disease) 09/2006
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2006

Drug/Important Bio-Agent (IBA)

57	AsbestosIBA 01/2022 - 04/2006
8	CarcinogensIBA 01/2022 - 07/2009
3	Serpentine Asbestos (Chrysotile)IBA 01/2020 - 03/2016
2	IronIBA 01/2022 - 04/2016
2	Talc FDA Link 01/2020 - 01/2017
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 07/2008
2	ORALIT (ORS)IBA 01/2017 - 02/2012
2	OsteopontinIBA 06/2013 - 07/2008
2	Xylenes (Xylene)IBA 11/2008 - 09/2006
2	Benzene (Benzole)IBA 11/2008 - 09/2006
2	SolventsIBA 11/2008 - 09/2006
2	TolueneIBA 11/2008 - 09/2006
1	Polycyclic Aromatic Hydrocarbons (Polynuclear Aromatic Hydrocarbons)IBA 01/2022
1	MetalsIBA 01/2021
1	Amphibole AsbestosIBA 01/2020
1	CarbonIBA 01/2020
1	Vehicle Emissions (Emissions, Vehicle)IBA 01/2020
1	tremolite (bredigite)IBA 01/2020
1	Silicon Dioxide (Silica)FDA LinkGeneric 01/2020
1	taconiteIBA 04/2016
1	Glyphosate (Roundup)IBA 01/2016
1	Coal (Coals)IBA 09/2015
1	SmokeIBA 02/2014
1	Integrin-Binding SialoproteinIBA 06/2013
1	2-Naphthylamine (2 Naphthylamine)IBA 12/2012
1	AntioxidantsIBA 12/2012
1	Formaldehyde (Formol)FDA Link 07/2012
1	EndotoxinsIBA 02/2012
1	Cyclic HydrocarbonsIBA 11/2009
1	Glycoproteins (Glycoprotein)IBA 07/2008
1	Chlorinated HydrocarbonsIBA 09/2006
1	titanium dioxide (Titania)FDA Link 09/2004